Stop spreading the news

In this very well thought-out report, the groups from the Universities of Colorado and Southern California have rightfully indicated that readmission not only signifies possible failure of the selected treatment modality but also affects healthcare costs and patient quality of life. They concluded that patients receiving medical therapy might be readmitted for delayed thoracic endovascular aortic repair (TEVAR) without immediate or 1-year penalty. Given the observed equipoise, they recommended a randomized trial to decide the appropriate management of uncomplicated type B aortic dissection (uTBAD). 1 Yi J.A. Gupta R. Tat Q. Potter H.A. Han S.M. Fernando F. et al. Readmission after early thoracic endovascular aortic repair versus medical management of acute type B aortic dissection. J Vasc Surg. 2023; 77: 1387-1393 Abstract Full Text Full Text PDF Scopus (2) Google Scholar Their conclusion and recommendation are in alignment with our own society’s research priorities and numerous other investigators who have reached similar conclusions. 2 Tzeng E. Corriere M. Henke P. Schanzer A. Beck A. Shalhub S. et al. Updated research priorities of the Society for Vascular Surgery. J Vasc Surg. 2022; 76: 1432-1439 Abstract Full Text Full Text PDF PubMed Scopus (3) Google Scholar ,3 Weissler E.H. Osazuwa-Peters O.L. Melissa A. Greiner M.A. Hardy N.C. Kougias P. et al. Initial thoracic endovascular aortic repair vs medical therapy for acute uncomplicated type B aortic dissection. JAMA Cardiol. 2022; 8: 44-53 Crossref Scopus (3) Google Scholar Readmission after early thoracic endovascular aortic repair versus medical management of acute type B aortic dissectionJournal of Vascular SurgeryVol. 77Issue 5PreviewThe use of thoracic endovascular aortic repair (TEVAR) for the management of acute uncomplicated type B aortic dissection (TBAD) has increased. Although the results from early studies were promising, larger randomized trials evaluating TEVAR are lacking. It is also unclear where sufficient equipoise exists for such trials. In the present study, we evaluated the number of readmissions and unplanned operations after TEVAR vs those after medical management as the initial treatment of acute uncomplicated TBAD and the frequency of each treatment in this population. Full-Text PDF